BIOCRYST PHARM (BO1 BE) stock market data APIs
€8.9487
0(0%)
as of May 19, 2025
Try our APIs with
free plan!
BIOCRYST PHARM Financial Data Overview
There is no Profile data available for BO1.BE.
Prev. Close
8.9487
Open
8.9487
High
8.9487
Low
8.9487
52 wk Range
5.51-9.714
Market Cap
1 856 M
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BIOCRYST PHARM data using free add-ons & libraries
Get BIOCRYST PHARM Fundamental Data
BIOCRYST PHARM Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BIOCRYST PHARM News
New
BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)
BioCryst Pharmaceuticals, Inc. RESEARCH TRIANGLE PARK, N.C., May 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral...
BioCryst Pharmaceuticals Says FDA Grants Priority Review for Orladeyo in Children
BioCryst Pharmaceuticals (BCRX) said Wednesday that the US Food and Drug Administration has accepted PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years
BioCryst Pharmaceuticals, Inc. –FDA grants Priority Review of application, with PDUFA target action date of September 12, 2025– –ORLADEYO would be the first targeted oral prophylactic therapy ...
Best Momentum Stocks to Buy for May 9th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 9th: BioCryst Pharmaceuticals, Inc. BCRX: This biotechnology company has a Zacks Rank #1 a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
